Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC).
2014 ◽
Vol 32
(15_suppl)
◽
pp. 4503-4503
◽
2014 ◽
Vol 180
(5)
◽
pp. 499-507
◽
2013 ◽
Vol 23
(1)
◽
pp. 209-214
◽
2021 ◽